Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation

Shabnam Radbakhsh, Niki Katsiki, Raul D. Santos, Dimitri P. Mikhailidis, Christos S. Mantzoros, Amirhossein Sahebkar

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Statins are a class of cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Anti-inflammatory and antioxidant properties, as well as improvement of endothelial function and plaque stabilization have also been proposed as parts of the pleiotropic effects of statins. Specialized pro-resolving mediators (SPMs) are endogenous lipid-derived molecules originating from ω-6 and ω-3 polyunsaturated fatty acids, such as arachidonic, docosahexaenoic and eicosapentaenoic acid that trigger and modulate the resolution of inflammation. Impaired SPM biosynthesis can lead to excessive or chronic inflammation and is implicated in the pathogenesis of several diseases. Exogenous administration of SPMs, including lipoxin, maresin, protectin, have been shown to improve both bacterial and viral infections, mainly in preclinical models, thus minimizing inflammation. Statin-triggered-SPM production in several in vitro and in vivo models may represent another anti-inflammatory pathway involving these drugs. This commentary discusses scientific publications on the effects of statins on SPMs and the resolution of inflammation process.

Original languageEnglish
Article number155211
JournalMetabolism: clinical and experimental
Volume132
DOIs
Publication statusPublished - Jul 2022

Fingerprint

Dive into the research topics of 'Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation'. Together they form a unique fingerprint.

Cite this